Current pharmacogenetic developments in oral anticoagulation therapy: The 
influence of variant VKORC1 and CYP2C9 alleles

Oldenburg, Johannes; Bevans, Carville G.; Fregin, Andreas; Geisen, Christof; Müller-Reible, Clemens; Watzka, Matthias

Item

ITEM ACTIONSEXPORT

Add to Basket

Please note that a newer version of this item is available:
https://pure.mpg.de/pubman/item/item_2080489_2

DetailsSummary

Released

Journal Article

Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles

MPS-Authors

/persons/resource/persons137600

Bevans, Carville G.
Department of Structural Biology, Max Planck Institute of Biophysics, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Oldenburg, J., Bevans, C. G., Fregin, A., Geisen, C., Müller-Reible, C., & Watzka, M. (2007). Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles. Thrombosis and Haemostasis, 98(3), 570-578.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0024-D8B1-F

Abstract

There is no abstract available